Fate Therapeutics Inc
Change company Symbol lookup
Select an option...
FATE Fate Therapeutics Inc
WES Western Midstream Partners LP
BAC Bank of America Corp
UNH UnitedHealth Group Inc
MSFT Microsoft Corp
BWA BorgWarner Inc
PAC Grupo Aeroportuario del Pacifico SAB de CV
AAPL Apple Inc
SPH Suburban Propane Partners LP
PH Parker-Hannifin Corp

Health Care : Biotechnology | Small Cap Growth
Company profile

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.


Last Trade
0.00 (0.00%)
B/A Size

Market Hours

Closing Price
Day's Change
0.41 (1.42%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Bank stocks get a boost after jobs data

8:57 am ET November 1, 2019 (MarketWatch)

Financial stocks got an early boost Friday, as a stronger-than-expected government jobs report (http://www.marketwatch.com/story/us-adds-128000-new-jobs-in-october-in-stronger-than-expected-employment-report-2019-11-01) helped drive up Treasury yields. The SPDR Financial Select Sector ETF (XLF) rose 0.7% in premarket trading, after being unchanged just before the jobs data was released. Meanwhile, futures for the Dow Jones Industrial Average rose 111 points. Among some of the financial ETF's more heavily weighted components, shares of Bank of America Corp. (BAC) rallied 1.2%, compared with a pre-data gain of 0.3%; J.P. Morgan Chase & Co. (JPM) hiked up 0.8% vs. a pre-data gain of 0.3%; Citigroup (C) was unchanged pre-data, but was recently up 0.8%; Wells Fargo & Co. (WFC) jumped 1.1%, after being unchanged just before the data. The yield on the 10-year Treasury note rose 2.6 basis points to 1.717%. Higher longer-term yields can increase what banks earn from funding longer-term assets, like loans, with shorter-term liabilities.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 01, 2019 08:57 ET (12:57 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.